Quest Diagnostics Inc , the world's largest provider of diagnostic testing services, is working with France's national health agency to build an expanded database for BRCA1 and BRCA2 gene mutations to better determine patient hereditary risks of breast and ovarian cancer. Other medical testing companies and public laboratories can participate in the project, called BRCA Share, for which Quest will charge an annual fee in return for access to the curated database, Madison, New Jersey-based Quest said on Tuesday.